DBV Technologies | DBVT - Operating Expenses


DBV Technologies reported $37.05M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Amarin USD 51.48M 113K Dec/2025
BioCryst Pharmaceuticals USD -553.84M 700.01M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
DBV Technologies USD 37.05M 4.06M Sep/2025
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Galectin Therapeutics USD 11.29M 1.64M Jun/2024
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Incyte USD 5.62B 4.5B Mar/2026
Insmed USD 506.24M 7.31M Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
United Therapeutics USD 5.9B 5.1B Mar/2026